Latest AlphaLISA(TM) Immunoassay Kits Reduce Customers' Time, Labor and Materials; Enhance Research Efforts for Cancer, Alzheimer's, Diabetes, HIV, Inflammation and Cardiovascular Disease
April 4, 2008--PerkinElmer, Inc. (NYSE: PKI), a global leader in Health Sciences and Photonics, announced the release of eight new AlphaLISA(TM) immunoassay kits in conjunction with the Society for Biomolecular Sciences' (SBS) 14th Annual Conference and Exhibition. These latest innovations include research reagents and assays for investigating HIV, cancer, central nervous system disorders, cardiovascular disorders, and diabetes(a).
AlphaLISA is a line of highly sensitive "No-Wash" immunoassay reagents offering a wide dynamic range and easy automation for analysis of biomarkers and other analytes. The technology allows researchers to replace multi-step, cumbersome ELISAs with a high throughput screening (HTS) platform, significantly reducing the time, labor and materials necessary for processing complex samples... PerkinElmer's Press Release -
Blog Archive
-
▼
2008
(79)
-
▼
April
(15)
- AstraZeneca and Washington University In St. Louis...
- Baxter : Study Results of GAMMAGARD S/D and GAMMAG...
- Medivation : Dimebon Improves Significantly Think...
- Lexicon : Clinical Data for LX6171, a Drug Candida...
- Intellect Neurosciences : ... Grant Requirements f...
- Allon at BIO Europe Partnering Meeting
- PerkinElmer : New Innovations to Strengthen Drug D...
- Exelgen : Two New Major Drug Discovery Collaborat...
- Satoris : Collaboration to Validate Early Alzheime...
- PHC Pioneer Behavioral Health : Phase I Alzheimer'...
- Pharmathene : Recombinant Butyrylcholinesterase (r...
- QuantRx , FluoroPharma : Technology Platform to I...
- Memory Pharmaceuticals : Advance Development and C...
- EPIX Pharmaceuticals : Phase 2a Alzheimer's Data a...
- Lilly : First Phase III Trial for Treatment of Alz...
-
▼
April
(15)